ELMMB logo
Facebook logo Twitter logo
Menu
Drug Alerts and Withdrawals

Drug Alerts and Withdrawals

Within the UK, the Medicines and Healthcare products Regulatory Agency (MHRA), an executive agency of the Department of Health aim to enhance and safeguard the health of the public by ensuring that medicines and medical devices work and are acceptably safe. No product is risk-free. Underpinning their work lie robust and fact-based judgements to ensure that the benefits to patients and the public justify the risks.

  • The Medicines and Healthcare products Regulatory Agency (MHRA) is the government agency which is responsible for ensuring that medicines and medical devices work, and are acceptably safe.
  • No product is risk-free. Underpinning the work of the MHRA lie robust and fact-based judgements to ensure that the benefits to patients and the public justify the risks.
  • The MHRA keep watch over medicines and devices, and take any necessary action to protect the public promptly if there is a problem.
  • The MHRA aim to make as much information as possible publicly available. The MHRA enable greater access to products, and the timely introduction of innovative treatments and technologies that benefit patients and the public.
  • The MHRA encourage everyone - the public and healthcare professionals as well as industry - to tell us about any problems with a medicine or medical device, so that we can investigate and take any necessary action. To find out more about the MHRA click here...

When the MHRA, or occasionally another regulatory body in another country, such as the FDA, release advice, it is sometime necessary to produce additional local guidance.  This aims to be both clear and concise advice to healthcare professionals on the local action required to implement or respond to alerts issued by the MHRA or other bodies.  These memorandums are available below for reference, once they have been circulated to the relevant professionals in primary and secondary care:

MHRA News Stories.

 26th May 2020              MHRA Press Release - MHRA supports use of remdesivir as the first medicines to treat COVID-19 in the UK
 6th May 2020                MHRA Press Release - NEW Yellow Card COVID-19 reporting site
12th February 2020      MHRA Press Release  - Integrated Yellow Card reporting now available in 93% of GP practices in the UK
19th November 2019   MHRA Press Release - Ranitidine Oral Solution & Tablets recall
                                                     
                                                 


MHRA Company-led Drug alerts

click here to access the most recent alerts

Items In This Category

 TitleCreatedDownload
application/pdfInhixa sol for injection Class 4 medicines recall april 2018.pdf (263KB)27/04/2018Download
 Inhixa soln for injection. Class 4 medicines defect information april 2018 
application/pdfLynparza Class 3 MEDICINES RECALL 120318_astra zeneca.pdf (135KB)12/03/2018Download
 AstraZeneca is recalling batch NG327 as the level of olaparib polymorphic form L exceeds the registered specification limit. As a precautionary measure additional batches are also being recalled... 
application/pdfVentolin Accuhaler Class 2 Medicines recall 0218 EL_18_A03-Final.pdf (436KB)22/02/2018Download
 Glaxo Wellcome UK Limited is recalling Lots 786G and 754P of Ventolin Accuhaler 200mcg because a manufacturing issue with these Lots has been identified which has resulted in a small number of units... 
application/pdfSeretide Accuhaler Class 2 Medicines recall 0218_EL(18)A_04.pdf (290KB)22/02/2018Download
 Glaxo Wellcome UK Limited is recalling LOT 5K8W of Seretide Accuhaler 50/250mcg because a manufacturing issue with this Lot has been identified which has resulted in a small number of units not... 
application/pdfEsmya _ulipristal_ uterine fibroids -MHRA letter February 2018.pdf (62KB)15/02/2018Download
  
application/pdfMagnevist and Omniscan sol for inj_class 2 medicines recall MHRA.pdf (153KB)02/02/2018Download
 All unexpired stock of the above products marketed by Bayer plc and GE Healthcare AS is being recalled and should immediately be quarantined. This follows a safety review of the gadolinium EL (18)... 
application/pdfMolipaxin 100mg capsules Class 2 medicines recall.pdf (229KB)04/01/2018Download
 A precautionary recall is being carried out due to the potential that during manufacture of the batch, the metal detector may not have functioned and therefore that the presence of metal particles... 
application/pdfBuccolam (midazolam) oromucosal soln pf. - Class 4 medicines defect infformation.pdf (315KB)07/12/2017Download
 As outlined in the DHCP attached, we ask you share this information with your patients' parents and caregivers, and with age-appropriate patients, during your interactions with them going forward to... 
application/pdfLipitor (atorvastatin) 80mg fc tablets Class 2 medicines recall MHRA.pdf (133KB)27/11/2017Download
 Pfizer is recalling the above batches as a precaution due to an out of specification result for microbiological testing during routine stability studies on a batch of the product which was not... 
application/pdfAdrenaline auto-injector MHRA updated advice Aug17.pdf (255KB)26/09/2017Download
  
application/pdfNovopen ECHO & Novopen 5 Nordisk -company led recall 240817.pdf (626KB)24/08/2017Download
  
application/pdfDutor gastro-resistant capsules (Duloxetine) Class 3 medicines recall.pdf (238KB)14/08/2017Download
 Torrent Pharma (UK) Ltd is recalling the above batches as a precaution because out of specification results for dissolution were obtained during routine stability testing 
Page: [1] [2] [3] [4] [5] [6]